The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Development of new interventions and treatment for schistosomiasis morbidity control. Australia has played a lead role in Parasitology research. It is vital to remain at the forefront in combating the human and livestock diseases that parasites cause. Vaccine assessment and the large scale analysis of patient tissues are vital to the biotechnology, agriculture and pharmaceutical industries with outcomes leading to innovative strategies for control. Politically there is value as it is altruistic ....Development of new interventions and treatment for schistosomiasis morbidity control. Australia has played a lead role in Parasitology research. It is vital to remain at the forefront in combating the human and livestock diseases that parasites cause. Vaccine assessment and the large scale analysis of patient tissues are vital to the biotechnology, agriculture and pharmaceutical industries with outcomes leading to innovative strategies for control. Politically there is value as it is altruistic to develop new tools, technologies and treatments for the Asia/Pacific region. Economically, Australia will have first pass at developing the intellectual property arising. As well, the therapies would be developed locally to the benefit of Australia's human therapeutics industry and bio-reagent manufacturers.Read moreRead less
Foreign DNA is a danger signal for mammalian cells. This project investigates how cells normally respond to foreign DNA, and is relevant to understanding how the body fights infections, particularly by viruses. The results will help us to design more effective treatments for infectious disease. Studying responses to DNA will also promote the design of new treatments for the autoimmune disease lupus, and help improve technologies or treatments where DNA is introduced into cells or tissues. This ....Foreign DNA is a danger signal for mammalian cells. This project investigates how cells normally respond to foreign DNA, and is relevant to understanding how the body fights infections, particularly by viruses. The results will help us to design more effective treatments for infectious disease. Studying responses to DNA will also promote the design of new treatments for the autoimmune disease lupus, and help improve technologies or treatments where DNA is introduced into cells or tissues. This includes gene therapy, new strategies for vaccination, and the production of proteins as drugs by biotechnology. The project will promote National Research Priorities in the areas of preventative healthcare, ageing well ageing productively, breakthrough science and new technologies.Read moreRead less
Development of disulphide-rich peptides for drug design. Peptides are an outstanding source of potential drug leads. This project seeks to build on earlier breakthroughs by developing stable, peptide-based drugs to combat cancer and autoimmune diseases. The peptides, derived from natural sources, are anticipated to provide drug leads that can ultimately lead to treatments for these diseases.
Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin. The team is developing a new improved way to vaccinate against deadly infectious diseases such as influenza and malaria. They believe their Nanopatch technology will boost the power of seasonal influenza vaccination and could even solve vaccine shortages in an influenza pandemic. This is because the Nanopatch needs much less vaccine per person than a conventional syringe. They also predict that vaccine ....Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin. The team is developing a new improved way to vaccinate against deadly infectious diseases such as influenza and malaria. They believe their Nanopatch technology will boost the power of seasonal influenza vaccination and could even solve vaccine shortages in an influenza pandemic. This is because the Nanopatch needs much less vaccine per person than a conventional syringe. They also predict that vaccines delivered with a Nanopatch will require less refrigeration than conventional vaccines and can be safely administered by individuals without medical training, making the benefits of vaccination accessible to more people more cheaply, even in remote areas.Read moreRead less